Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

2081 - The frequency of somatic AKT1 mutation among Japanese breast and endometrial cancer patients (46P)


18 Nov 2017


Poster lunch


Translational Research;  Endometrial Cancer;  Breast Cancer


Takuji Seo


Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653


T. Seo1, T. Shimoi2, A. Hamada3, A. Shimomura4, K. Sudo2, E. Noguchi2, K. Yonemori4, C. Shimizu2, Y. Fujiwara2, K. Tamura2

Author affiliations

  • 1 Department Of Breast And Medical Oncology, National Cancer Center Hospital, 1040045 - Tokyo/JP
  • 2 Department Of Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Division Of Clinical Pharmacology & Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, 1040045 - Tokyo/JP
  • 4 Department Of Experimental Therapeutics, National Cancer Center Hospital, 104-0045 - Tokyo/JP


Abstract 2081


The PI3K/AKT/mTOR pathway is frequently activaed across many cancers. AKT1 is a subfamily of serine/threonine protein kinases, affecting cell survival, proliferation and invasion. The prior reports from Western country have shown AKT1 mutation in 3-6% of breast cancer and in 2-3% of endometrial cancer. However, the clinico-pathological features of AKT1 E17K mutation in Asian female cancers is unclear. In this study, we examined breast cancer samples and endometrial cancer samples for mutation in AKT1 hotspot at our institution.


For patients with breast cancer and endometrial cancer, we retrospectively analyzed tissue samples preserved between January 2008 and June 2015 in a biobank at national cancer center hospital. We extracted DNA and determined AKT1 mutation with PNA-LNA clamp methods. Kaplan-Meier analysis was performed to analyze relapse-free survival (RFS) after surgery and overall survival (OS) for breast cancer patient.


A total of 469 patients were analyzed. Three hundred and twenty-nine patients were breast and 140 were endometrial cancer. The median age was 52 (range 22-90). In breast cancer patients, 305 patients were initially stage I to III, and thirty-two patients were initially Stage IV. The number of tumor subtype was hormone receptor (HR) positive and HER2 negative tumor; 248 (74%), HR positive and HER2 positive tumor; 44 (13%), HR negative and HER2 positive tumor; 28 (8%), and Triple negative tumor; 17 (5%), respectively. We detected AKT1 mutation in 24 patients (7.3%) of breast-cancer patients and 7 patients (5.0%) of endometrial-carcinoma patients. In breast cancer patients, there were 176 relapses and 32 deaths. Median RFS was 79 months in patients with AKT1 wild type and 75 months in patients with AKT1 mutation (p-value:0.77).


We detected AKT1 mutation in 31 patients (6.6%) of 469 breast and endometrial cancer. RFS in breast cancer patients is not significantly different by AKT1 mutation status.

Clinical trial identification

Legal entity responsible for the study

National Cancer Center Hospital




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.